Format

Send to

Choose Destination
Br J Psychiatry. 2010 May;196(5):346-53. doi: 10.1192/bjp.bp.109.066019.

Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis.

Author information

1
Academic Clinical Psychiatry, University of Sheffield, Sheffield, UK. t.tsoi@sheffield.ac.uk

Abstract

BACKGROUND:

The benefits and harms of bupropion as an aid for smoking cessation in schizophrenia remain uncertain.

AIMS:

To summarise the current evidence for efficacy and safety of bupropion as treatment for nicotine dependence in schizophrenia.

METHOD:

Systematic review and random-effects meta-analysis of randomised controlled trials (RCTs) comparing bupropion with placebo or alternative therapeutic control in adult smokers with schizophrenia.

RESULTS:

Twenty-one reports from seven RCTs were included. Biochemically verified self-reported smoking cessation rates after bupropion were significantly higher than placebo at the end of treatment (risk ratio (RR) = 2.57, P = 0.004) and at 6 months (RR = 2.78, P = 0.05). Expired carbon monoxide level was significantly lower with bupropion at the end of therapy (P = 0.002) but not at 6 months (P = 0.37). There was no significant difference in positive (P = 0.28) or negative symptoms (P = 0.49) between the bupropion and the placebo group.

CONCLUSIONS:

Bupropion increases the rates of smoking abstinence in smokers with schizophrenia, without jeopardising their mental state.

PMID:
20435957
DOI:
10.1192/bjp.bp.109.066019
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Cambridge University Press
Loading ...
Support Center